ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

For adults with moderate-to-severe plaque psoriasis

ILUMYA® IS IN IT FOR THE LONG HAUL*

MOST PEOPLE TAKING ILUMYA® SEE CLEARER SKIN AFTER 2 DOSES, AND 5 YEARS LATER, THOSE RESULTS ARE STILL GOING STRONG

*Based on 5-year data.

What is ILUMYA®?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

SELECTED IMPORTANT SAFETY INFORMATION

ILUMYA® is not for everyone, only your doctor can determine if it's right for you. Do not take ILUMYA® if you are allergic to ILUMYA® or any of its ingredients. ILUMYA® may lower your ability to fight infections and may increase your risk of infections. Before starting treatment, your doctor should check you for tuberculosis and infections.

Please read the Important Safety Information on pages 14 and 15 of this brochure and the enclosed full Prescribing Information and Medication Guide.

Visit ILUMYA.com for more information.

About those plaques on your skin...

While no one knows the exact cause of plaque psoriasis, scientists do know that it starts in your immune system.

In plaque psoriasis, your skin cells grow more rapidly than normal, rising to the surface of your skin in days rather than weeks. This causes the plaques, redness, and flakes you see on your skin.

That's why it's important to have a treatment that moves past a surface-level approach and treats your symptoms at the source.

How ILUMYA® works

ILUMYA® GETS TO THE SOURCE AND WORKS BELOW THE SURFACE

ILUMYA® (tildrakizumab-asmn) works differently than most other biologics to help stop plaque psoriasis in its tracks.

- ILUMYA® blocks an important molecule called IL-23 that plays a key role in making psoriasis worse
- When ILUMYA® blocks the IL-23 molecule, other molecules that cause psoriasis to get worse are also blocked
- Blocking these molecules slows down the growth of skin cells
- With less buildup of skin cells, fewer psoriasis symptoms are likely to occur

Scan to learn more about how ILUMYA® works.

ILUMYA® (tildrakizumab-asmn) may increase the risk of infection compared with placebo (23% vs 22%). In clinical trials, the most common (≥1%) infections were upper respiratory infections.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL



Find long-lasting results with ILUMYA®

Cycling through treatments can take its toll. That's why it's good to know that with ILUMYA® (tildrakizumab-asmn), you can get your moderate-to-severe plaque psoriasis under control and keep it under control.

CLEARER AFTER 2 DOSES

6 out of 10 people were clear or almost clear in as little as **12 weeks**.

1 YEAR AND COUNTING

8 out of 10 people who had 75% clearer skin with ILUMYA® at 7 months were still clearer after **1 year** of treatment.

STILL GOING STRONG AT 5 YEARS

9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results **5 years into treatment**.

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

With results that keep going strong, ILUMYA® is with you for the long haul

BEFORE	AFTER 2 DOSES	AFTER 3 DOSES
		
Psoriasis plaques on the arm	Psoriasis plaques on the arm begin to clear after 12 weeks on ILUMYA®	Psoriasis plaques on the arm continue to clear after 28 weeks on ILUMYA®
		
Psoriasis plaques on the back and arms	Psoriasis plaques on the back and arms begin to clear after 12 weeks on ILUMYA®	Psoriasis plaques on the back and arms continue to clear after 28 weeks on ILUMYA®

BEFORE	AFTER 1 DOSE	AFTER 2 DOSES
		
Psoriasis plaques on the scalp	Psoriasis plaques on the scalp begin to clear after 4 weeks on ILUMYA®	Psoriasis plaques on the scalp continue to clear after 12 weeks on ILUMYA®

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

Established safety profile over 5 years

When choosing a treatment for moderate-to-severe plaque psoriasis, it's important to consider the potential benefits and side effects.

- Across 3 clinical studies, the rates of serious infection were the same for those taking ILUMYA® (tildrakizumab-asmn) and those who were given an injection without medicine in it (0.3%)
- The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%)

NO ROUTINE LAB MONITORING NEEDED

Unless your doctor thinks it's necessary, no routine lab monitoring is needed beyond initial screening.

WORKS REGARDLESS OF BMI* OR WEIGHT

In clinical trials of people treated with ILUMYA®, those who had a higher BMI had similar skin clearing and low risk of serious infection as those who didn't have this condition.

*Body mass index (BMI) is a measure of body fat based on height and weight.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

Discover the dosing advantage of ILUMYA®

ILUMYA® (tildrakizumab-asmn) isn't a topical that you have to apply a few times a day. It isn't a pill that you have to take daily. In fact, ILUMYA® offers fewer doses per year than most other biologics used to treat moderate-to-severe plaque psoriasis. So now, your treatment doesn't have to be a daily, weekly, or even monthly chore.



HOW IS ILUMYA® GIVEN?

ILUMYA® (tildrakizumab-asmn) is an injection given at your healthcare provider's office, so you don't need to worry about forgetting or missing your treatment.

It is also possible to receive your treatment at another location, like an infusion center, that provides similar healthcare services. If you're interested in receiving your injection at an alternate location, ILUMYA SUPPORT® will work with your physician to coordinate.

Since ILUMYA® is an injection administered by a healthcare provider, it is covered by Medicare Part B, with a supplement, as a medical benefit.

See how to get started with ILUMYA® on page 12.

The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

ILUMYA SUPPORT
LIGHTING THE WAY®

Financial support and more

ILUMYA SUPPORT LIGHTING THE WAY® PROGRAM

Once you and your dermatologist have decided on ILUMYA® (tildrakizumab-asmn), you'll have access to the ILUMYA SUPPORT LIGHTING THE WAY® program.

This program was designed to guide you along your treatment journey and can help you:

- Understand your insurance coverage
- Explore your financial options
- Start ILUMYA® quickly and easily
- Stay on track with your doses
- Get support and useful information along the way

AFFORDABLE TREATMENT OPTIONS FOR ANY LEVEL OF COVERAGE

Find the support you need to get you going and keep you going on your journey to clearer skin.

- Eligible patients with **Medicare Part B** and a supplement may pay as little as $0 for each dose of ILUMYA® (tildrakizumab-asmn)
- If you have commercial insurance (usually through your employer), you may be eligible for the **ILUMYA® Copay Program** and pay as little as $0 per dose
- If you do not have enough insurance coverage or do not have insurance at all, you may be eligible to receive ILUMYA® at no cost through the **Patient Assistance Program**

Your choice of Medicare plan affects your treatment

Medicare Part B helps pay for outpatient services needed to administer prescriptions. Because ILUMYA® is a biologic that can only be administered in a healthcare provider's office, it's covered under Medicare Part B (with a supplement).

Scan to learn more about your options with ILUMYA SUPPORT® and savings.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

How to get started on ILUMYA®

ASK

Ask your dermatologist to submit your ILUMYA SUPPORT LIGHTING THE WAY® enrollment form.

Once your paperwork is submitted, finish enrolling by visiting **ILUMYA.com/activate** or calling **855-4ILUMYA (855-445-8692)**.

By activating, you agree to receive marketing and other loyalty program text messages and emails, including messages sent using an autodialer. You understand that consent is not required as a condition of purchase.

CONFIRM

We will confirm if your prescription is covered by your insurance provider and if you are qualified for ILUMYA® (tildrakizumab-asmn) financial support programs.

PREPARE

Prepare for a call from your ILUMYA SUPPORT® team (855-445-8692) or your specialty pharmacy to receive your coverage benefits. They will let you know when your prescription will be delivered, which will help you schedule your first treatment appointment.

SCHEDULE

Schedule an appointment for your first dose.

You will receive your injection by a healthcare provider at either your physician's office or an alternate location that provides similar healthcare services. If a different site offers more convenient hours or location, the ILUMYA SUPPORT® team will work with your physician to verify the alternative center of care.

Talk to your physician about what's best for you in terms of where to receive your treatment.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

What is ILUMYA®?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA®?

Do not use ILUMYA® if you have had a severe allergic reaction to ILUMYA® or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA® is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA® and may treat you for TB before you begin treatment with ILUMYA® if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA®.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA®, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section **"What is the most important information I should know about ILUMYA®?"**
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA®.
- are pregnant or plan to become pregnant. It is not known if ILUMYA® can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA® passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA® is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA®?

ILUMYA® may cause serious side effects. See "What is the most important information I should know about ILUMYA®?"

The most common side effects of ILUMYA® include: upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA® to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the accompanying full Prescribing Information and Medication Guide for ILUMYA® and discuss any questions with your doctor.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

"It's almost too good to be true."

Mike Q., 72

Started ILUMYA® in June 2020

Individual results may vary.

The most common (≥1%) adverse reactions for ILUMYA® (tildrakizumab-asmn) compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%).

Scan to discover real ILUMYA® patient stories.

ILUMYA®
tildrakizumab-asmn
Injection 100 mg/mL

SUN PHARMA